You are here
- Home
- Therapy Areas
- Neuroscience
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study.
- Disease
- Alzheimer's Disease, mild cognitive impairment
- Drug Name
- AstraZeneca Neuroscience Development Drugs
- Generic Name
- AZD5213
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- IIa
- Start Date
- Jan 18, 1971
- Study Name
- D3030C00005
- Study Id
- D3030C00005
- ClinicalTrials.gov ID
- NCT01548287
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
